1 / 9

Elbasvir + Grazoprevir + /- RBV in GT 1 Cirrhotics & Null Responders C-WORTHY

Phase 2b. Treatment Naïve and Treatment Experienced. Elbasvir + Grazoprevir + /- RBV in GT 1 Cirrhotics & Null Responders C-WORTHY. Lawitz E, et al. Lancet 2015;385:1075-86. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1 C-WORTHY Study: Features.

jeb
Download Presentation

Elbasvir + Grazoprevir + /- RBV in GT 1 Cirrhotics & Null Responders C-WORTHY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2b Treatment Naïve and Treatment Experienced Elbasvir + Grazoprevir +/- RBV in GT 1 Cirrhotics& Null RespondersC-WORTHY Lawitz E, et al. Lancet 2015;385:1075-86.

  2. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1C-WORTHY Study: Features Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  3. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1C-WORTHY: Study Design Cohort 1 (Cirrhosis) 0 12 18 24 30 Week SVR12 Cohort 1Treatment-Naive Cirrhosis(n=123) EBR + GZR + RBV n =31 n = 29 SVR12 EBR + GZR n = 32 SVR12 EBR+ GZR + RBV n =31 SVR12 EBR + GZR Abbreviations: EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin Drug DosingElbasvir: 50 mg once dailyGrazoprevir: 100 mg once dailyRibavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  4. Elbasvir + Grazoprevir+/- Ribavirin in HCV GT1C-WORTHY: Study Design Cohort 2 (Null Responders) 0 12 18 24 30 Week SVR12 Cohort 2Null Responders( n=130) EBR + GZR + RBV N=32 N=33 SVR12 EBR + GZR N=33 SVR12 EBR + GZR + RBV N=32 SVR12 EBR + GZR Abbreviations: EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin Drug DosingElbasvir: 50 mg once dailyGrazoprevir: 100 mg once dailyRibavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  5. Elbasvir + Grazoprevir+/- Ribavirin in HCV GT1C-WORTHY: Baseline Characteristics Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  6. Elbasvir + Grazoprevir+/- Ribavirin in HCV GT1C-WORTHY: Results for Naïve Cirrhotics (Cohort 1) C-WORTHY: SVR 12* by Treatment Duration and Regimen 28/31 28/29 31/32 29/31 12-Week Regimen 18-Week Regimen Abbreviations: EBR = elbasvir; GZR= grazoprevir; RBV = ribavirin*Analysis per protocol: excluding patients who dropped out due to reasons other than virologic failure Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  7. Elbasvir + Grazoprevir+/- Ribavirin in HCV GT1C-WORTHY: Results for Null Responders (Cohort 2) C-WORTHY: SVR 12* by Treatment Duration and Regimen 30/32 30/33 33/33 31/32 12-Week Regimen 18-Week Regimen Abbreviations: EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin*Analysis per protocol: excluding patients who dropped out due to reasons other than virologic failure Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  8. Elbasvir + Grazoprevir+/- Ribavirin in HCV GT1C-WORTHY: Adverse Events Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  9. Elbasvir + Grazoprevir+/- Ribavirin in HCV GT1C-WORTHYStudy: Conclusions Source: Lawitz E, et al. Lancet 2015;385:1075-86.

More Related